Form 4: Spruce Biosciences Director Granted 30,000 Stock Options

Spruce Biosciences, Inc. Director Daniel K. Spiegelman was granted 30,000 stock options with an exercise price of $0.1162, vesting over time and upon certain conditions.

Summary

• Daniel K. Spiegelman, a Director of Spruce Biosciences, Inc. (SPRB), was granted 30,000 stock options.
• The options have an exercise price of $0.1162 per share.
• The grant date for these options was July 22, 2025.
• The options are exercisable from July 22, 2025, and expire on July 21, 2035.
• The shares underlying the options vest on the first anniversary of the grant date.
• Full vesting will occur on the date of the Company's 2026 annual stockholder meeting, subject to continuous service.
• The options will also vest in full upon a Change in Control, as defined in the 2020 Equity Incentive Plan.
• Following this transaction, Daniel K. Spiegelman beneficially owns 30,000 derivative securities directly.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates alignment of a director's interests with shareholders through equity compensation, a standard practice.

Positives

• Granting stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The options have a long expiration date (July 21, 2035), providing a significant window for potential value creation.

Negatives

• The grant of new options could lead to future dilution if exercised, though this is a standard component of equity compensation.

Risks

• The value of the stock options is dependent on the future stock price of Spruce Biosciences, Inc., which is subject to market volatility and company performance.
• Vesting is contingent on continuous service, meaning the director must remain with the company for the options to fully vest under normal conditions.

Future Outlook

The stock options are designed to incentivize long-term commitment and performance, with vesting tied to future service and potential corporate events like a Change in Control.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain talent, and to align the interests of leadership with those of shareholders. This practice is part of standard executive and director compensation packages.

Comparison to Industry Standards

• Stock option grants to directors are a standard component of compensation across various industries, including biotechnology.
• While the specific number of options (30,000) and the exercise price ($0.1162) are specific to Spruce Biosciences, the mechanism of granting options with vesting conditions tied to service and performance is consistent with compensation practices at comparable companies.
• Many small to mid-cap biotech firms often use equity compensation to conserve cash and incentivize long-term value creation, similar to companies that also grant options to their non-executive directors.

Corporate Governance

Related Party Transactions

• The grant of 30,000 stock options to Daniel K. Spiegelman, a Director of Spruce Biosciences, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of director's interests with shareholder value creation.

Next Steps

• The options will begin to vest on the first anniversary of the grant date (July 22, 2025).
• The options will fully vest by the Company's 2026 annual stockholder meeting, subject to continuous service.
• The options may be exercised by the director at any time after vesting and before the expiration date of July 21, 2035.

Key Dates

Keywords

Spruce Biosciences, SPRB, stock options, director compensation, insider transaction, equity incentive plan, corporate governance, beneficial ownership